STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Spero Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Anson-managed entities reported beneficial ownership of 1,615,469 shares of Spero Therapeutics common stock, representing 2.9% of the 55,910,641 shares outstanding. The holdings are disclosed on a Schedule 13G/A dated for the event 06/30/2025 and signed on 08/14/2025 by representatives of Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo and Moez Kassam.

The filing states the shares are held by the Fund and that the position is held in the ordinary course of business and not to influence control of the issuer. Voting and dispositive power over the 1,615,469 shares is shown as shared (no sole power reported). The filing cites the issuer's outstanding share count from the issuer's May 13, 2025 quarterly report.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Anson group disclosed a passive 2.9% stake in SPRO, a non-controlling position that is unlikely to force near-term corporate changes.

The Schedule 13G/A reports 1,615,469 shares (2.9% of 55,910,641 shares). The filing classifies the position as held in the ordinary course of business and not intended to influence control, consistent with passive investor reporting thresholds. Shared voting and dispositive power is indicated across the Anson entities. For investors, this is a transparent ownership disclosure rather than an activist move; it signals interest but not control.

TL;DR: The disclosure documents beneficial ownership and shared authority but shows no group formation or control intent, so governance impact appears limited.

The filing lists multiple affiliated filers and confirms shared voting/dispositive power over 1,615,469 shares (2.9%). Item 10 certification states the stake was not acquired to change control. No members of a group, no greater-than-5% ownership, and no solicitation or group formation are reported. From a governance perspective, this is routine transparency with no immediate governance implications disclosed.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Anson Funds Management LP
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Anson Management GP LLC
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Tony Moore
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Anson Advisors Inc.
Signature:/s/ Amin Nathoo
Name/Title:Amin Nathoo, Director
Date:08/14/2025
Signature:/s/ Moez Kassam
Name/Title:Moez Kassam, Director
Date:08/14/2025
Amin Nathoo
Signature:/s/ Amin Nathoo
Name/Title:Amin Nathoo, Director
Date:08/14/2025
Moez Kassam
Signature:/s/ Moez Kassam
Name/Title:Moez Kassam, Director
Date:08/14/2025

FAQ

What stake does Anson report in SPRO?

Anson reports beneficial ownership of 1,615,469 shares, equal to 2.9% of SPRO's 55,910,641 outstanding shares.

Does the filing indicate Anson intends to influence control of Spero (SPRO)?

No. The filing certifies the shares were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.

Who signed the Schedule 13G/A for Anson?

Signatures include Tony Moore for Anson Funds Management LP and Anson Management GP LLC, and Amin Nathoo and Moez Kassam for Anson Advisors Inc.; all dated 08/14/2025.

What type of reporting persons are listed?

Reporting persons include investment adviser and private fund entities and individuals, classified as IA, PN, HC, OO, FI, CO, IN depending on the filer.

What voting and dispositive powers are reported?

The filing reports 0 sole voting/dispositive power and 1,615,469 shared voting and dispositive power for each reporting person.
Spero Therapeuti

NASDAQ:SPRO

SPRO Rankings

SPRO Latest News

SPRO Latest SEC Filings

SPRO Stock Data

137.31M
42.63M
24.43%
15.56%
0.9%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE